Abstracts for the British Association of Dermatologists 102nd Annual Meeting, 05–07 July 2022, SEC Glasgow, Scotland: British Journal of Dermatology: Vol 187, No S1

I consent to Wiley Online Library’s Terms of Use and processing of my personal data as disclosed in Wiley’s Privacy Policy.I consent to my personal information being transferred outside of the People’s Republic of China as laid out in Wiley’s Privacy Policy.*(Optional) I consent to special offers, newsletter & promotions from Wiley. See Privacy Policy for more details.

Tools

Submit an article

Subscribe to this journal

Click here to view the latest trending articles from the British Journal of Dermatology

BAD journals

Volume 4, Issue 6
December 2024
Volume 47, Issue 12
Pages: 2075-2350
December 2022

Skin Health and Disease

BJD Clinical Trials

Don't miss our video infographic about fast-track clinical trials!

BAD journals

Volume 4, Issue 6
December 2024

British Journal of Dermatology

Journal list menu

Tools

Follow journal

British Journal of Dermatology: Volume 187, Issue S1

Special Issue:Abstracts for the British Association of Dermatologists 102nd Annual Meeting, 05–07 July 2022, SEC Glasgow, Scotland

Download PDFs

Abstracts for the British Association of Dermatologists 102nd Annual Meeting, 05–07 July 2022, SEC Glasgow, Scotland

Issue Information

Issue Information

Foreword

Foreword

Officers and Committee

Officers and Committee

Clinical Vice President

Clinical Vice President

Guest Speakers

Guest Speakers

Orals

O01: Vitiligo diagnosis is associated with an increase in new-onset depression and anxiety: a population-based cohort study in the UK

O02: Risk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune-modifying therapies: a nationwide cohort study in the OpenSAFELY platform

O03: Effect modification of biologic survival by patient characteristics: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register

O04: Efficacy and safety of dupilumab in children aged ≥ 6 months to < 6 years with moderate-to-severe atopic dermatitis

O05: ‘A raised P3NP is a matter of time’: replacing P3NP with FIB-4 for monitoring of methotrexate-related liver fibrosis

O06: A randomized controlled trial assessing the effectiveness and safety of ciclosporin vs. methotrexate in the treatment of severe atopic eczema in children and young people: the TREatment of severe Atopic eczema Trial (TREAT)

O07: Carbonylated proteins as markers of oxidative stress and their association with filaggrin genotype in atopic eczema

O08: Skin tumours in England 2013–2019: in-depth reporting of a new consensus classification to improve prospective data extraction and clinical interpretation

O09: A national review of porocarcinoma epidemiology in England 2013–2018

O10: National Merkel cell carcinoma epidemiology and mortality-related risk factors in England 2004–2018

Registrar papers

RF02: Hospitalization from COVID-19 is most frequently observed in patients with atopic dermatitis treated with systemic corticosteroids, and in particular when systemic corticosteroids are used in combination with another immunomodulatory treatment: lessons from the global SECURE-AD registry

RF03: Risk factors for paradoxical eczema in patients with psoriasis on biologics: a nested case–control study

RF04: Galea vs. periosteum: impact of excision depth on outcomes for cutaneous squamous cell carcinoma of the scalp

RF05: Checkpoint inhibitor associated bullous cutaneous adverse immune-related events: a multicentre observational study

Clinicopathological cases

CPC01: Clinically distinct attributes of histologically confirmed keratoacanthoma and cutaneous squamous cell carcinomas

CPC02: An unusual case of rash secondary to the COVID-19 vaccine is presented with a review of the literature

CPC03: Generalized essential telangiectasia response to treatment with oral dabigatran: a case report

CPC04: Immune checkpoint inhibitor therapy and psoriasis: a case series

CPC05: Plasma cell mucositis: a complex and challenging condition

CPC06: Cutaneous metastases from triple-negative lobular breast cancer in the contralateral breast in a zosteriform pattern

CPC07: Erythromelalgia associated with small-fibre neuropathy

CPC08: New-onset pemphigus foliaceus following COVID-19 vaccine

CPC09: A contrasting diagnosis: iododerma

CPC10: First reported case of parvovirus triggering painful widespread livedoid vasculopathy: another virus causing hypercoagulability?

CPC11: Bromoderma in a patient with chronic obstructive pulmonary disease

CPC12: Alopecia due to chronic graft-versus-host disease

CPC13: Comparative study of p16, p53 and Ki67 immunostaining indicates that keratoacanthoma and cutaneous squamous cell carcinoma are clinicopathologically distinct entities

CPC14: A rare adult presentation of cutaneous Langerhans cell histiocytosis associated with acute transformation of myeloid leukaemia

Ethnic diversity and identity

ED01: Eczema Assessment and Severity Index scoring in skin of colour

ED02: Skin cancers in skin of colour survey: current unmet needs

Health service delivery, management research and Getting It Right First Time (GIRFT) symposium

GIRFT01: The long-term costs of COVID-19 for patients with skin cancer: a retrospective single-centre review of multidisciplinary team skin cancer cases and outcomes from 2019 to 2021

GIRFT02: The influence of the COVID-19 pandemic on Breslow thickness and outpatient malignant melanoma service provision in an Irish Dermatology centre

GIRFT03: The number needed to treat metric: a further marker of the impact of COVID-19 on malignant melanomas

GIRFT04: Teleconsultations in paediatric dermatology: a UK-wide clinician survey

GIRFT05: The use of an online teledermatology platform with patient-submitted history and images for waiting list recovery in dermatology

GIRFT06: Patient questionnaire-based triage improves outcomes for psoriasis referrals

Posters

P01: ‘Age is just a number’: a rare facial blistering eruption in an 18-year-old female

P02: Toxic epidermal necrolysis after COVID-19 booster vaccination: is a mixed vaccination schedule a risk?

P03:The unusual suspect

P04: Phototherapy to treat a COVID-19 vaccine reaction

P05: Eosinophilic fasciitis triggered by intensive exercise

P06: Oral mucosal melanoma: not the same as the cutaneous variant

P07: A rare case of perforating calcific elastosis, showing the importance of clinicopathological correlation

P08: Familial mutilating vulval granulomatous inflammation associated with steatocystoma multiplex

P09: Unilateral cutaneous sarcoidosis of the radiotherapy field after breast cancer

P10: Bullous morphoea with objectively assessed response to mycophenolate mofetil: a case with literature review

P11: Leser-Trélat sign: can it follow COVID-19 infection?

P12: Just a bruise? Angiosarcoma in long-standing leg lymphoedema

P13: Adenoid cystic carcinoma: a rare adnexal neoplasm that uncommonly presents in the skin

P14: Cutaneous metastasis from salivary duct carcinoma: a case and review of literature

P15: Twenty years of the UK Dermatology Clinical Trials Network: past, present and future

P16: Gender and sexual identity: unmet dermatological needs of LGBTQ+ individuals and how dermatologists can provide better care: a qualitative analysis of a cross-sectional survey

P17: Transitional care arrangements in epidermolysis bullosa: a prototype for wider dermatology

P18: Prescribing antipsychotics in dermatology: a national survey of clinical experience, physician confidence and training needs

P19: Fast-track occupational health dermatology clinic for healthcare workers: trends and burden of occupational dermatoses during the COVID-19 pandemic

P20: The impact of a novel dermatology teaching programme on medical students’ understanding of and engagement with dermatology